N/A N=84 Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit
Multiple Sclerosis
Primary: Change in Timed Up and Go Test From Day 1 to Day 42 — 0.1; -0.8 seconds — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=74 Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis
Radiation Induced Fibrosis to the Head and Neck
Primary: Improvement in Neck Fibrosis — 13; 13 participants
Phase 3 N=9 Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
Cystic Fibrosis
Primary: Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs — 3; 5; 8; 0 participants
Phase 3 N=294 Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
Renal Failure Chronic Requiring Hemodialysis
Primary: Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean — -0.5; -4.0 grams per liter — p=0.011
Phase 2 N=10 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
Phase 4 N=311 A Comparison of Long-acting Injectable Medications for Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Efficacy Failure — 49; 47 participants
Phase 3 N=221 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Breast Cancer
Primary: Progression-free Survival — 8.0; 4.0 months — p=0.078
Phase 2 N=8 Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy
Peripheral Neuropathy · Type 1 Diabetes
Primary: Intra-epidermal Nerve Fiber Density (IENFD) Fibers Per mm — 6.3; 3.0; 5.2; 3.0 fibers per mm
Phase 2 N=10 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Exfoliation Syndrome · Ocular Hypertension · Open Angle Glaucoma
Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg
Phase 2 N=44 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Atypical Hemolytic-Uremic Syndrome
Primary: Percentage of Patients With Complete TMA Response — 73.2 Percentage of Participants
Phase 3 N=873 Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Diabetes Mellitus, Type 2
Primary: The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group — -1.29; -1.64; -2.07; -2.15 percentage — p=0.0587
Phase 3 N=52 Nitric Oxide Administration for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Mean PaO2/FiO2 Ratio — 115.6; 115.9 mmHg — p=>0.05
N/A N=152 Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma
Asthma
Primary: Number of Inhaled Corticosteroid (ICS) Prescriptions Refilled (Confirmed by Primary Care Physician) — 18; 32 Participants — p=0.87
Phase 3 N=367 Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)
Bipolar 1 Disorder
Primary: Change From Baseline in Young Mania Rating Scale (Y-MRS) Total Score at Day 21 — -14.4; -14.9; -10.9 Score on a scale — p=0.0136
Phase 4 N=265 Telemedicine Outreach for Post Traumatic Stress in CBOCs
Posttraumatic Stress Disorder
Primary: Change in PTSD Symptom Severity (PDS) — -5.31; -1.07 units on a scale — p=0.002